ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /反応

Dimethylformamide → (1R,5S)-3-(4-methyl-5-(6-(trifluoromethyl)-1H-indazol-4-yl)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide

HRID 58122
印刷

反応式

HRID 58122 の反応式
[CH3:1][C:2]1[C:7]([C:8]2[CH:16]=[C:15]([C:17]([F:20])([F:19])[F:18])[CH:14]=[C:13]3[C:9]=2[CH:10]=[N:11][NH:12]3)=[CH:6][N:5]=[C:4]([N:21]2[CH2:26][C@@H:25]3[C@@H:23]([CH2:24]3)[CH:22]2[C:27]([OH:29])=O)[N:3]=1.[NH4+].[Cl-].C[N:33](C([O:39]N1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(CC)CC.CN([CH:66]=[O:67])C>>[C:66]([OH:67])([C:17]([F:20])([F:19])[F:18])=[O:39].[CH3:1][C:2]1[C:7]([C:8]2[CH:16]=[C:15]([C:17]([F:19])([F:18])[F:20])[CH:14]=[C:13]3[C:9]=2[CH:10]=[N:11][NH:12]3)=[CH:6][N:5]=[C:4]([N:21]2[CH2:26][C@@H:25]3[C@@H:23]([CH2:24]3)[CH:22]2[C:27]([NH2:33])=[O:29])[N:3]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 5

HCID 6228DimethylformamideHCID 8471TriethylamineHCID 25517Ammonium ChlorideHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 89794893(1R,5S)-3-(4-methyl-5-(6-(trifluoromethyl)-1H-indazol-4-yl)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid

生成物 2

HCID 6422
Trifluoroacetic acid
HCID 89794848(1R,5S)-3-(4-methyl-5-(6-(trifluoromethyl)-1H-indazol-4-yl)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide収率 3.2%

実験手順

In a 4 mL vial equipped with a magnetic stir bar were mixed (1R,5S)-3-(4-methyl-5-(6-(trifluoromethyl)-1H-indazol-4-yl)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (80 mg, 0.198 mmol), NH4Cl (21.22 mg, 0.397 mmol), HATU (90 mg, 0.238 mmol) and Et3N (0.083 mL, 0.595 mmol) in DMF (2 mL). The resulting brown solution was stirred overnight. The product was purified by preparative HPLC, eluting with a gradient of 25-50% ACN (containing 0.035% TFA) in H2O (containing 0.05% TFA). The pure fractions were lyophilized to give a TFA salt of the title compound as a white solid (3.3 mg, 3.2%). 1H NMR (400 MHz, CD3OD) δ ppm 0.78-0.86 (m, 2H), 1.88 (ddd, J=12.06, 7.26, 4.67 Hz, 1H), 2.09-2.15 (m, 1H), 2.25-2.29 (m, 3H), 3.82 (dd, J=10.61, 5.05 Hz, 1H), 3.92-3.96 (m, 1H), 4.61 (d, J=5.31 Hz, 1H), 7.28 (d, J=1.01 Hz, 1H), 7.93-7.95 (m, 2H), 8.27 (s, 1H); ESI-MS m/z [M+H]+ calc'd for C19H17F3N6O, 403.2. found 403.4.

後処理

  1. customIn a 4 mL vial equipped with a magnetic stir bar
  2. customThe product was purified by preparative HPLC
  3. washeluting with a gradient of 25-50% ACN (containing 0.035% TFA) in H2O (containing 0.05% TFA)

出典と根拠

ORDレコード
ord-4ffd930c775c4774ad4539256ff2549f
出典データセット
uspto-grants-2016_09
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09434743B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート